Therapy after single oral agent failure: adding a second oral agent or an insulin mixture?

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Type 2 diabetes management often requires combination therapy when initial oral agents are insufficient.
• Glibenclamide plus metformin (G+M) is a common regimen, but alternatives are sought to improve glycemic control and reduce side effects.
• Insulin therapy, particularly with rapid-acting analogs, offers flexible glycemic management options.

Purpose of the Study:

• To compare the efficacy and safety of an insulin lispro mixture (25% insulin lispro and 75% NPL) twice daily plus metformin (Mix25+M) versus glibenclamide plus metformin (G+M).
• To evaluate glycemic response, including hemoglobin A1C (A1C) and postprandial glucose (PPG) levels.
• To assess hypoglycemia rates, patient symptoms, and overall treatment tolerability.

Main Methods:

• A randomized, open-label, 16-week parallel study involving 597 patients with type 2 diabetes inadequately controlled on a single oral agent.
• Patients received either Mix25+M or G+M.
• Key outcome measures included changes in A1C, PPG, hypoglycemia incidence and rate, and patient-reported symptoms. A subset underwent standardized meal tests.

Main Results:

• Both Mix25+M and G+M significantly improved A1C, with no significant difference between groups (-1.87% vs. -1.98%, p=0.288).
• Mix25+M demonstrated significantly lower 2-hour postprandial plasma glucose (9.05 vs. 12.31 mmol/l, p<0.001) and a higher achievement rate of PPG targets (80% vs. 48%, p<0.001).
• While overall hypoglycemia rates were similar, Mix25+M showed a lower incidence and rate of nocturnal hypoglycemia (1% vs. 5%, p<0.01) and reduced polyuria (p<0.001).

Conclusions:

• In type 2 diabetes patients inadequately controlled on metformin or sulfonylurea, Mix25+M provides comparable overall glycemic control to G+M.
• Mix25+M offers advantages in reducing postprandial hyperglycemia and nocturnal hypoglycemia.
• The insulin lispro mixture regimen also led to fewer hyperglycemic symptoms, suggesting improved patient tolerability and quality of life.